RYTM RHYTHM PHARMACEUTICALS, INC.

Nasdaq Pharmaceutical Preparations DE CIK: 0001649904
AI RATING
SELL
72% Confidence

Investment Thesis

While Rhythm Pharmaceuticals demonstrates strong revenue growth (+45.8% YoY) and improving loss trajectory, the company faces critical cash runway constraints with $45.1M annual free cash burn against only $62.1M in cash, providing approximately 1.4 years of operations. Despite positive commercialization trends, the absence of operating profitability and persistent inability to cover interest from operations present material solvency risks that require near-term improvement or capital infusion.

Strengths

  • + Strong topline revenue growth of 45.8% YoY demonstrates commercial traction
  • + Improving loss profile with net loss declining 2.7% YoY and EPS improving 28.3% YoY
  • + Excellent liquidity position with 4.17x current ratio and 3.89x quick ratio

Risks

  • ! Critical cash runway constraint: negative $45.1M FCF against $62.1M cash (~1.4 years coverage)
  • ! Deeply unprofitable with -92.6% net margin and -87.1% operating margin, cannot service debt from operations
  • ! Significant debt burden of $98.3M with negative interest coverage ratio of -11.0x

Key Metrics to Watch

Financial Metrics

Revenue
60.1M
Net Income
-55.6M
EPS (Diluted)
$-0.83
Free Cash Flow
-45.1M
Total Assets
442.3M
Cash
62.1M

Profitability Ratios

Gross Margin N/A
Operating Margin -87.1%
Net Margin -92.6%
ROE -45.3%
ROA -12.6%
FCF Margin -75.1%

Balance Sheet & Liquidity

Current Ratio
4.17x
Quick Ratio
3.89x
Debt/Equity
0.80x
Debt/Assets
46.3%
Interest Coverage
-11.01x
Long-term Debt
98.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-07T10:27:11.272183 | Data as of: 2026-03-31 | Powered by Claude AI